Business
Re Licence Agreement
Re Licence Agreement.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n \n PROTEOME SCIENCES plc \n\n PRESS RELEASE \n\n Licence Agreement in HTS Stroke \n\nJune 28, 2006. Proteome Sciences plc (\"Proteome Sciences\") is pleased to\nannounce a licence agreement with one of the top 10 global leaders in clinical\ndiagnostics to use its biomarkers for the detection, diagnosis and monitoring\nof stroke. This is a new area for the licencee who has determined not to\ndisclose its identity at this time for competitive reasons. The biomarkers were\ndiscovered and validated using a combination of different proteomic approaches\navailable for external use through the proprietary ProteoSHOP® platform.\n\nStroke is the brain equivalent of a heart attack. Blood must flow in and\nthrough the brain for it to function. If its flow is obstructed by a blood clot\nmoving to the brain or by narrowing or blocking of blood vessels, the brain\nloses its energy supply, causing damage to tissues leading to stroke.\n\nAnnually, 15 million people worldwide suffer a stroke. Of these, 5.5 million\ndie and another 5 million are left permanently disabled, placing a burden on\nfamily and community.\n\nStroke is the third leading cause of death in the US (160,000 deaths) with\nannual costs of $57.9bn for stroke-medical related costs and disability and the\nsingle most common cause of severe disability. 750,000 people are diagnosed in\nthe US annually having new or recent strokes.\n\nUnder the research licence, a number of Proteome Sciences biomarkers will be\ntested in stroke for inclusion on a new panel for the licencee's\nhigh-throughput diagnostic platforms. No financial details were disclosed.\n\nThe preliminary announcement of Proteome Sciences results for the year ended\n31st December, 2005 will be released by 30th June, 2006.\n\nChristopher Pearce, CEO of Proteome Sciences, said:\n\n\" This licencee is world renowned in clinical diagnostics and has built a\nstrong customer base ideally placed to introduce and support new stroke\ndiagnostic products globally. This reflects their commitment to develop\ninnovative assays and solutions to address the major unmet diagnostic and\nprognostic needs in stroke.\n\nThey have been impressed by Proteome Sciences' ProteoSHOP® technology to\ndiscover novel biomarkers in blood and to progress these rapidly for the market\nplace. This agreement brings important new biomarkers to their I...